$156.85
-5.43-3.35%
Last update: Nov 5, 4:00 PM

The average analyst price target for Palvella Therapeutics is $163.63, 4.3% above the current price. Of 17 analysts, 17 rate it Buy. Targets range from $38 to $250. The latest change came on Oct 16, 2026, when William Blair initiated coverage of Palvella Therapeutics with an Outperform rating.
Price Target Range — 9 Quarters
Analyst Consensus — 17 Analysts
Rating Trend — Last 9 Months